Table 16Peripheral vascular disease: Clopidogrel compared with aspirin (PAD subgroup from CAPRIE)

Domains pertaining to strength of evidenceMagnitude of effectaStrength of evidence
Number of studies; number of subjectsRisk of bias (design/quality)ConsistencyDirectnessPrecisionSummary effect size (95% confidence interval)High, moderate, low, insufficient
Cardiovascular mortality (fatal stroke, fatal MI, other vascular death from Table 7 of 1996 Lancet publication)
1/N=11592Low (RCT/Good)NAIndirectImpreciseRR 0.78 (0.60 to 1.01)Moderate
All-cause mortality, revascularization, major bleeding, withdrawals due to adverse events not reported for PAD subgroup

Relative risks calculated by OR EPC using StatsDirect.

From: Appendix F, Strength of evidence

Cover of Drug Class Review: Newer Antiplatelet Agents
Drug Class Review: Newer Antiplatelet Agents: Final Update 2 Report [Internet].
Ketchum K, Peterson K, Thakurta S, et al.
Portland (OR): Oregon Health & Science University; 2011 Jun.
Copyright © 2011 by Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.